News Search Results
Dec 15, 2025, 16:01 ET Kodiak Sciences Announces Proposed Public Offering of Common Stock
Calif., Dec. 15, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced that it has commenced an underwritten
More news about: Kodiak Sciences Inc.
Dec 15, 2025, 14:58 ET Roche receives FDA approval for first diagnostic tests to identify HER2-positive metastatic breast cancer patients eligible for ENHERTU
RocheFounded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics
More news about: Roche
Dec 15, 2025, 13:45 ET BioFlorida Fuels Innovation: Awards $90,000 in Annual Pitch Competition
progressive multiple sclerosis and ALS, with FDA clearance to move forward with advanced trial studies.Asha Therapeutics, a Tampa based biotechnology company, earned $30,000 as the Emerging Florida winner for their pioneering therapeutic platform. Under the leadership of Co-founder, Chief Scientific
More news about: BioFlorida
Dec 15, 2025, 09:15 ET LifeNet Health Advances Regenerative Medicine with the Acquisition of Biopreservation Leader, Tissue Testing Technologies
15, 2025 /PRNewswire/ -- LifeNet Health, a global leader in regenerative medicine, has acquired Tissue Testing Technologies LLC (T3), a biotechnology company specializing in biopreservation. T3 's advanced proprietary technologies and services preserve living cells and tissues for clinical and
More news about: LifeNet Health
Dec 15, 2025, 09:05 ET Pivot Bio Announces Additions to Senior Management
contributed to multiple insect-control biotechnology products in North and South America, including Trecepta, SmartStaxPro, Intacta, BollGard and ThryvOn for corn, soy and cotton, respectively. He held several leadership roles across R&D in regulatory as well as biotechnology product development organizations. Prior
More news about: Pivot Bio, Inc
Dec 15, 2025, 08:45 ET Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has completed the transfer of the Investigational New Drug application
More news about: Anixa Biosciences, Inc.
Dec 15, 2025, 08:30 ET Leucid Bio and Syenex Announce Strategic Collaboration for In Vivo CAR-T Cell Engineering
and CHICAGO, Dec. 15, 2025 /PRNewswire/ -- Leucid Bio ("Leucid" or the "Company"), a privately-held biotechnology company developing innovative Chimeric Antigen Receptor T-cell (CAR-T) therapies using its proprietary lateral CAR platform, and Syenex, an open-science
More news about: Leucid Bio
Dec 15, 2025, 08:30 ET Link Cell Therapies Launches with Vision of Advancing CAR-T Therapies in Solid and Liquid Tumors
[email protected] Link Cell Therapies Link Cell Therapies ("Link") is a biotechnology company based in South San Francisco, California that was founded in 2022 by Robbie Majzner, MD and Crystal Mackall, MD at Stanford University.
More news about: Link Cell Therapies
Dec 15, 2025, 08:00 ET Diakonos Oncology to Present Corporate Overview and Participate in Panel at 2026 Biotech Showcase
clinical-stage biotechnology company developing a new generation of immunotherapies to treat challenging and aggressive cancers, today announced it will participate in the Biotech Showcase in San Francisco, CA, from January 13-15, 2026. This premier event is for private and micro-mid-cap biotechnology companies
More news about: Diakonos Oncology
Dec 15, 2025, 08:00 ET Leadgene Biosolutions, Inc., (Formerly CYTENA BPS), Announces Corporate Rebranding to Mark a New Phase of Growth within the Leadgene Group
Biosolutions, Inc. (formerly CYTENA BPS), following its transition out of the BICO Group, now officially integrates with Leadgene Biomedical, a biotechnology company specializing in recombinant proteins, antibodies, and diagnostic reagent development with integrated CRO/CDMO services. This alignment enables
More news about: Leadgene Biosolutions
Dec 15, 2025, 08:00 ET Leadgene Biosolutions, Inc., (Formerly CYTENA BPS), Announces Corporate Rebranding to Mark a New Phase of Growth within the Leadgene Group
Biosolutions, Inc. (formerly CYTENA BPS), following its transition out of the BICO Group, now officially integrates with Leadgene Biomedical, a biotechnology company specializing in recombinant proteins, antibodies, and diagnostic reagent development with integrated CRO/CDMO services. This alignment enables
More news about: Leadgene Biosolutions
Dec 15, 2025, 08:00 ET Kenai Therapeutics Announces First Patient Dosed in Phase 1 REPLACE™ Clinical Trial of Neuron Replacement Cell Therapy RNDP-001 for Idiopathic Parkinson's Disease
SAN DIEGO, Dec. 15, 2025 /PRNewswire/ -- Kenai Therapeutics, a clinical-stage biotechnology company pioneering next generation approaches to cure neurological conditions, today announced that the first patient has been dosed in its Phase
More news about: Kenai Therapeutics/BIOCOM
Dec 15, 2025, 08:00 ET Immusoft Secures FDA Orphan Drug Designation for ISP-002 in MPS II, a Progressive Lysosomal Storage Disease
SAN FRANCISCO, Dec. 15, 2025 /PRNewswire/ -- Immusoft of CA, a clinical-stage biotechnology company pioneering engineered B cell therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation
More news about: Immusoft
Dec 15, 2025, 06:30 ET Polyhydroxyalkanoate (PHA) Market worth $265.2 million by 2030 - Exclusive Report by MarketsandMarkets™
(US), Kaneka Corporation (Japan), Ecomann Biotechnology Co., Ltd. (China), RWDC Industries (Singapore), Bluepha Co., Ltd. (China), Newlight Technologies, Inc. (US), Ningbo Tianan Biologic Materials Co., Ltd. (China), Biomer (Germany), Beijing PhaBuilder Biotechnology Co., Ltd. (China), and TerraVerdae Bioworks
More news about: MarketsandMarkets
Dec 15, 2025, 05:23 ET Healthcare IT Market Set to More Than Double by 2030 Growing at 15.24% CAGR, Reports Mordor Intelligence
tools, bioinformatics platforms), by application (genomics & transcriptomics, proteomics & metabolomics), by end-user (pharmaceutical & biotechnology companies, academics), and geography (North America, Europe, Asia-Pacific, and More).Agilent Technologies, Illumina Inc, PerkinElmer,
More news about: Mordor Intelligence Private Limited
Dec 15, 2025, 05:14 ET Breast Pump Market Set to Grow at an Impressive CAGR of 8.75% Through 2035 | 8.12 USD Billion | Vantage Market Research
market research reports and actionable intelligence across healthcare, biotechnology, and advanced cell therapies. Our globally recognized insights empower stakeholders to make informed decisions, anticipate trends, and capitalize
More news about: Vantage Market Research
Dec 15, 2025, 05:00 ET Minghui Pharmaceutical Announces FDA clearance of IND to Initiate Global Phase Ⅲ Trials of MHB018A, a Subcutaneous Single-Domain IGF-1R Antibody, in Thyroid Eye Disease
IGF-1R therapy for patients with TED.About Minghui PharmaceuticalFounded in 2018, Minghui Pharmaceutical is a near-commercial biotechnology innovator with two complementary growth engines: a robust clinical oncology portfolio built on its proprietary antibody-drug conjugate (ADC) platform
More news about: Minghui Pharmaceutical
Dec 15, 2025, 04:00 ET MEDEZE Receives Frost & Sullivan's 2025 Southeast Asia Company of the Year Recognition for Leadership in Stem Cell Banking and Regenerative Medicine
innovation, and market responsiveness. Its integrated operational model, financial strength, and commitment to sustainable growth exemplify leadership in biotechnology and position it at the forefront of Southeast Asia's transition toward licensed regenerative therapies.Each year, Frost & Sullivan presents
More news about: Frost & Sullivan
Dec 15, 2025, 04:00 ET MEDEZE Receives Frost & Sullivan's 2025 Southeast Asia Company of the Year Recognition for Leadership in Stem Cell Banking and Regenerative Medicine
innovation, and market responsiveness. Its integrated operational model, financial strength, and commitment to sustainable growth exemplify leadership in biotechnology and position it at the forefront of Southeast Asia's transition toward licensed regenerative therapies.Each year, Frost & Sullivan presents
More news about: Frost & Sullivan
Dec 15, 2025, 04:00 ET Ascletis Announces Positive Topline Results from U.S. Phase I Study of ASC50, a Potential Best-in-Class Oral Small Molecule IL-17 Inhibitor
https://voovmeeting.com/dm/eb7KovQX2hYD.About Ascletis Pharma Inc.Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases.
More news about: Ascletis Pharma Inc.
Dec 15, 2025, 01:28 ET Viva Biotech's invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion.
pharmaceutical ingredient, and the Group expects to continue its business cooperation with Arthrosi.Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate (sUA) levels,
More news about: Viva Biotech
Dec 15, 2025, 01:06 ET Viva Biotech's invested and incubated company, Arthrosi, has entered into an acquisition agreement with Sobi for a total transaction value of up to US$1.5 billion.
pharmaceutical ingredient, and the Group expects to continue its business cooperation with Arthrosi.Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate (sUA) levels,
More news about: Viva Biotech
Dec 14, 2025, 19:22 ET Patient Enrolment Completed in Phase 2 aGvHD Clinical Trial
Cynata Therapeutics Limited (ASX: "CYP" or "Cynata"), a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that patient enrolment has been completed in its Phase 2 clinical trial of CYP-001
More news about: Cynata Therapeutics
Dec 13, 2025, 15:57 ET Sobi to acquire Arthrosi Therapeutics, strengthening pipeline for the potential treatment of gout
/PRNewswire/ -- Sobi® (STO: SOBI) has entered into a definitive agreement to acquire Arthrosi Therapeutics, Inc. (Arthrosi), a private late-stage biotechnology company focused on developing a next-generation treatment for gout. The acquisition strengthens Sobi's gout franchise by adding pozdeutinurad (AR882),
More news about: Swedish Orphan Biovitrum AB
Dec 13, 2025, 15:52 ET Sobi to acquire Arthrosi Therapeutics, strengthening pipeline for the potential treatment of gout
/PRNewswire/ -- Sobi® (STO: SOBI) has entered into a definitive agreement to acquire Arthrosi Therapeutics, Inc. (Arthrosi), a private late-stage biotechnology company focused on developing a next-generation treatment for gout. The acquisition strengthens Sobi's gout franchise by adding pozdeutinurad (AR882),
More news about: Swedish Orphan Biovitrum AB